Sidney Clevinger, MD
Family Medicine · Ocala, FLNPI 1760461974
Payments from drug & device makers
What this record shows
This record is dominated by gifts: $109,604 of the $110,332 with a category attached, or 99.3%. Tosoh Bioscience, Inc. accounts for 99.3% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $110,054 and has fallen 100.0% since, to $14 in 2025. Among family medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 34 payments — averaging $3245.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tosoh Bioscience, Inc.$110K
- Amgen$146
- Medtronic$118
- Painteq LLC$104
- AstraZeneca$69
- Amarin Pharma, Inc.$51
- plus $240 from 9 others
Across 78 payments — averaging $2173.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$86K
- Eisai Inc.$55K
- Eli Lilly$17K
- Merck$8K
- Pfizer$3K
What the payments were for
- Food & beverage$7271%
- Education$10%
- Gifts$109,60499%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tosoh Bioscience, Inc. | 4 | $109,604 |
| Amgen(2 entities) | 5 | $146 |
| Medtronic | 1 | $118 |
| Painteq LLC | 1 | $104 |
| AstraZeneca | 4 | $69 |
| Amarin Pharma, Inc. | 3 | $51 |
| GSK | 3 | $50 |
| AbbVie(2 entities) | 2 | $41 |
| Pfizer | 2 | $32 |
| Sanofi Pasteur Inc. | 2 | $30 |
| Novo Nordisk | 2 | $27 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Antares Pharma, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Merck | 2 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- E2, ST AIA-PACK$54,802
- TES, AIA-PACK CALIBRATOR SET$54,802
- TES, ST AIA-PACK$54,802
- PA, ST AIA-PACK$54,802
- E2, ST Pack Calibrator Set$54,802
- PA, AIA-PACK Calibrator Set$54,802
- PA, AIA-PACK Linearity Set$27,401
- Wash Concentrate, AIA-PACK$27,401
- Diluent Concentrate, AIA-PACK$27,401
- Substrate Set II, AIA-PACK$27,401
- TES, AIA-PACK SAMPLE DILUTING SOL$27,401
- PA, AIA-PACK Sample Diluting Solution$27,401
- E2, AIA-PACK Sample Diluting Solution$27,401
- ClosureFast$118
- PAINTEQ$104
How this compares
$110,332 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 186 | $134,860 |
| OzempicSemaglutide | 85 | $88,248 |
| IngrezzaValbenazine Tosylate | 18 | $61,015 |
| MounjaroTirzepatide | 49 | $56,982 |
| JardianceEmpagliflozin | 76 | $56,845 |
| JanuviaSitagliptin Phosphate | 89 | $54,920 |
| XareltoRivaroxaban | 57 | $54,067 |
| LinzessLinaclotide | 48 | $37,492 |
| MyrbetriqMirabegron | 55 | $25,961 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $19,813 |
| TrulicityDulaglutide | 17 | $19,530 |
| EntrestoSacubitril/Valsartan | 12 | $18,482 |
| MultaqDronedarone Hcl | 15 | $14,688 |
| BrilintaTicagrelor | 51 | $12,473 |
| JanumetSitagliptin Phos/Metformin Hcl | 21 | $12,280 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $32 | $134,860186 claims |
| Novo NordiskOzempic, Levemir | $27 | $95,086143 claims |
| MerckJanuvia, Janumet | $10 | $67,201110 claims |
| AbbVieLinzess, Synthroid | $41 | $40,65689 claims |
| AstraZenecaBrilinta, Symbicort | $69 | $22,70876 claims |
| GSKTrelegy Ellipta | $50 | $19,81322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Ocala
- Lorn MillerOcala$53K
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
- Samuel GreenleePensacola$235K
- Kevin FitzgeraldStuart$198K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.